Skip to main content
Oryzon Genomics S.A. logo

Oryzon Genomics S.A. — Investor Relations & Filings

Ticker · ORY ISIN · ES0167733015 LEI · 95980063R15RDF29DK13 MC Manufacturing
Open in API
Filings indexed 142 across all filing types
Latest filing 2022-12-12 Earnings Release
Country ES Spain
Listing MC ORY

About Oryzon Genomics S.A.

https://www.oryzon.com/en

Oryzon Genomics is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on epigenetics. The company's primary focus is on creating personalized medicines for patients with cancer and central nervous system (CNS) disorders. Utilizing a proprietary epigenetic platform, Oryzon identifies and validates biomarkers and therapeutic targets to advance its pipeline of potential treatments. The company's therapeutic programs aim to address diseases with significant unmet medical needs by regulating gene expression without altering the underlying genetic sequence.

Recent filings

Filing Released Lang Actions
ORYZON presenta resultados finales del ensayo de Fase IIa ALICE con iadademstat en leucemia mieloide aguda en el congreso de la Sociedad Americana de Hematología, ASH-2022.
Earnings Release Classification · 99% confidence The document is titled as an 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information) communication, dated December 12, 2022, and explicitly states it is informing about the presentation of final results from a Phase IIa clinical trial (ALICE) at the American Society of Hematology (ASH-2022) conference. It includes a summary in an attached press release and provides details of the efficacy and safety data. The document structure, including the headline summarizing the presentation and the inclusion of forward-looking statements and contact information, strongly suggests this is an initial announcement of results rather than the full, comprehensive report itself (like an IR or 10-K). Since it is the initial announcement of periodical financial/clinical results, the most appropriate classification is 'Earnings Release' (ER), even though the results are clinical trial outcomes rather than standard quarterly revenue figures. It is the primary release of period-specific performance data. It is not a Call Transcript (CT) as it lacks Q&A, nor is it a full Investor Presentation (IP) or a general Regulatory Filing (RNS), as it fits the ER definition of an initial announcement of results. FY 2022
2022-12-12 Spanish
La sociedad comunica la conversión de obligaciones convertibles
Capital/Financing Update Classification · 98% confidence The document is a formal communication from ORYZON GENOMICS, S.A. announcing a specific corporate action related to financing. Key phrases include 'conversión de obligaciones' (conversion of bonds), 'aumento del capital social' (increase in share capital), 'emisión y puesta en circulación de nuevas acciones' (issuance and circulation of new shares), and the final resulting capital structure. This directly relates to changes in the company's capital structure and fundraising activities. This aligns perfectly with the definition for Capital/Financing Update (CAP). The document is short and is an announcement of an event, not a comprehensive report like a 10-K or IR.
2022-11-24 Spanish
Autorización de la FDA del IND para iniciar un estudio colaborativo de Fase II con el Fox Chase Cancer Center con iadademstat en pacientes con carcinomas neuroendocrinos.
Regulatory Filings Classification · 95% confidence The document is titled as an 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information) filing, which is typical for regulatory disclosures in Spain (CNMV). The content announces a specific corporate event: the FDA approval of an Investigational New Drug (IND) application for a Phase II study, and it explicitly states, 'Se adjunta como anexo la nota de prensa que será distribuida en el día de hoy' (The press release to be distributed today is attached as an annex). The document itself reads like a formal press release detailing clinical trial progress and scientific rationale. Since the document is an announcement that a press release is attached/being distributed, and it concerns significant operational/clinical news rather than routine financial reporting (like 10-K, IR, or ER), it fits best as a general regulatory announcement or a specific type of corporate update. Given the options, this is a significant corporate event announcement that is being disclosed via regulatory channels. It is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). It is a specific operational update. Since it is a formal announcement of a material event, and the text itself is the press release being distributed, it is most accurately classified as a Regulatory Filing (RNS) as a general disclosure mechanism, or potentially a Legal Proceedings Report (LTR) if the focus was on regulatory interaction, but RNS is the best fit for a general material announcement not covered by other specific codes. However, the content is highly specific to clinical development and regulatory milestones (FDA IND approval). This type of announcement often falls under general regulatory disclosure. Given the structure and content (announcing FDA IND approval and attaching the press release), it is a material corporate event disclosure. RNS is the most appropriate fallback for significant, non-standard disclosures. I will assign a high confidence score as it is clearly a formal regulatory disclosure of material information.
2022-11-09 Spanish
La Sociedad Remite información sobre los estados financieros del tercer trimestre de 2022
Interim / Quarterly Report Classification · 95% confidence The document is a quarterly financial update from Oryzon Genomics, S.A. for the third quarter of 2022. It includes a formal regulatory header, a press release summary, and detailed financial statements (Income Statement and Balance Sheet). While it is presented as a press release, it contains substantive financial data and analysis for an interim period, fitting the definition of an Interim/Quarterly Report (IR). 9M 2022
2022-11-02 Spanish
Motivo de la notificación: Persona con Responsabilidad de Dirección
Director's Dealing Classification · 99% confidence The document is titled 'STANDARD FORM FOR NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM'. This form explicitly details transactions (sales, purchases, etc.) conducted by directors or senior management (PDMRs) of the issuer. This directly corresponds to the definition of Director's Dealing, which covers personal share transactions by company directors and executives (insider trades). The filing code for this is DIRS.
2022-09-27 Spanish
ORYZON presenta datos preliminares de seguridad agregados y ciegos del estudio clínico de Fase IIb en marcha de vafidemstat en Trastorno Límite de la Personalidad en la European Conference on Mental H
Regulatory Filings Classification · 96% confidence The document is titled as an 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information) communication, mandated by Spanish securities law (Art. 227 of the Consolidated Text of the Securities Market Law). The content is a press release announcing preliminary safety data from a Phase IIb clinical trial (PORTICO) presented at a medical conference (ECMH). It includes key results, management quotes, and details about the trial, concluding with standard forward-looking statements and contact information. This format—a formal announcement of material, non-public information released outside of standard periodic reports (like 10-K or IR)—is characteristic of a general regulatory disclosure. Since it is not a specific report like an Annual Report (10-K), Interim Report (IR), or a specific corporate action notice (like DIV or CAP), and it is a formal announcement, it best fits the 'Regulatory Filings' (RNS) category, which serves as a catch-all for significant, non-standard regulatory disclosures in many jurisdictions, or potentially an Earnings Release (ER) if it were tied to financial results, but here it is scientific data presentation. Given the context of a formal communication of material, non-financial operational/clinical data mandated by regulators, RNS is the most appropriate general classification, although it shares characteristics with an ER in terms of immediacy. However, since it is not explicitly an 'Earnings Release' but a clinical data update, RNS is the safer fallback for significant regulatory announcements.
2022-09-16 Spanish

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.